Dry Eye Diagnostic Testing

Overview

The TFOS DEWS II framework places dry eye disease on a spectrum between aqueous-deficient and evaporative subtypes. No single test result confirms the diagnosis or identifies which subtype dominates, so diagnostic testing is built around that same premise. A complete workup layers a symptom questionnaire with a test of tear quantity, a test of tear film stability, and an assessment of ocular surface damage. Inflammatory biomarker testing and meibomian gland imaging get added when the initial picture is ambiguous, or when treatment planning depends on confirming meibomian gland dysfunction specifically.

Tear Quantity Testing

Schirmer Testing

The Schirmer test measures tear production directly with a paper strip placed in the inferior fornix. Performed without topical anesthesia, the strip itself stimulates corneal and conjunctival nerves, so the result reflects both basal and reflex tear secretion combined; this is the standard Schirmer I test. Performed with anesthesia (the basic secretion test), the reflex component is blunted and the result more closely isolates basal secretion. A Schirmer I value under 10 mm of wetting at 5 minutes is generally abnormal, suggesting aqueous tear deficiency.

Schirmer II is a distinct variant that deliberately provokes reflex tearing by stimulating the nasal mucosa. It tests the integrity of the trigeminal-mediated lacrimal reflex arc rather than baseline secretion, which makes it useful when neurotrophic or reflex-pathway dysfunction is suspected rather than pure glandular deficiency.

Tear Meniscus Height

At the slit lamp, the height of the tear meniscus along the lower lid margin gives a quick, noninvasive estimate of aqueous tear volume. A reduced meniscus height, typically under 0.2 mm, is a simple bedside sign of decreased tear volume that complements a formal Schirmer measurement.

Tear Film Stability & Composition

Tear Breakup Time (TBUT)

Fluorescein is instilled into the tear film and viewed under cobalt blue light; the time from the last blink until the first dry spot appears defines the tear breakup time. A TBUT under 10 seconds is generally abnormal and reflects tear film instability. It most often signals a deficient lipid layer in evaporative dry eye, though a short TBUT can occur with any subtype.

Tear Film Osmolarity

Tear hyperosmolarity is a central, unifying mechanism in dry eye pathophysiology. Point-of-care osmolarity systems, such as TearLab, measure it directly from a nanoliter tear sample. The absolute value isn't the only thing that matters diagnostically: high variability between the two eyes, or between visits, is itself clinically significant, since it reflects a loss of the tight homeostatic control that normal tear composition depends on, even when a single reading looks borderline.

Lipid Layer Interferometry

Interferometry analyzes the interference pattern of light reflected off the tear film to estimate lipid layer thickness and pattern. It assesses directly the layer whose deficiency drives evaporative dry eye, complementing TBUT, which measures the downstream consequence (instability) rather than the lipid layer itself.

Ocular Surface Damage Testing

Vital dyes stain damaged or devitalized cells directly, giving a visual map of surface injury that symptom scores and tear-quantity tests can't provide on their own.

• Fluorescein staining highlights the corneal epithelium: it penetrates wherever epithelial tight junctions have broken down, revealing punctate epithelial erosions.
• Lissamine green stains devitalized conjunctival and corneal epithelial cells with less patient irritation than the older rose bengal, making it well suited to detecting even mild ocular surface disease.
• The Van Bijsterveld score formalizes vital dye grading. It scores staining across three zones (nasal conjunctiva, cornea, and temporal conjunctiva), each on a 0–3 scale, and is used in Sjögren-associated dry eye severity grading.

Inflammatory Biomarker Testing

Matrix metalloproteinase-9 (MMP-9) is a nonspecific inflammatory marker elevated in the tears of dry eye patients. It degrades tight junction proteins and disrupts the corneal epithelial barrier. Point-of-care immunoassays such as InflammaDry detect elevated tear MMP-9 qualitatively, supporting the diagnosis and helping decide whether to start anti-inflammatory therapy rather than tear supplementation alone.

Meibomian Gland Imaging

Meibography uses infrared transillumination or non-contact imaging to visualize meibomian gland architecture directly, quantifying glandular atrophy or dropout. It is the structural counterpart to the functional tests above: a patient can have a normal interferometry reading yet still show significant gland dropout on meibography. The degree of dropout carries direct treatment implications, since glands that have already atrophied completely cannot be restored by gland-expression therapies.

Symptom Questionnaires

The Ocular Surface Disease Index (OSDI) is a validated patient-reported questionnaire that scores symptom frequency and its effect on vision-related quality of life. Because objective test results and subjective symptom severity often diverge in dry eye disease, OSDI is used both to grade severity at baseline and to track treatment response over time, a role none of the objective tests above are well suited to on their own.

High-Yield Pearls

• Schirmer I < 10 mm at 5 minutes and TBUT < 10 seconds are the two numeric cutoffs most likely to be tested directly.
• Fluorescein = corneal epithelium; lissamine green = conjunctival/corneal devitalized cells; Van Bijsterveld = the scoring system for vital dye staining.
• MMP-9 point-of-care testing (InflammaDry) detects ocular surface inflammation, independent of tear volume.
• Meibography images gland structure; interferometry measures lipid layer thickness (structure vs. function of the same evaporative pathway).
• OSDI is the standard patient-reported symptom instrument, used for both diagnosis and monitoring response to therapy.

Related Topics

Continue exploring Cornea & External Disease: